A compound formulation of EGF-modified paclitaxel micelles and EGF-modified emodin micelles enhance the therapeutic effect of ovarian cancer

References

• Adrianzen Herrera, D., et al., 2019. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence. Expert opinion on pharmacotherapy, 20 (1), 95–102.
   PubMed Web of Science ®Google Scholar
• Chen, Q., et al., 2020. Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention. Nano letters, 20 (1), 11–21.
   PubMed Web of Science ®Google Scholar
• Colombo, N., et al., ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. 2019. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Annals of oncology, 30 (5), 672–705.
   PubMed Web of Science ®Google Scholar
• Dai, G., et al., 2019. Emodin suppresses growth and invasion of colorectal cancer cells by inhibiting VEGFR2. European journal of pharmacology, 859, 172525.
   PubMed Web of Science ®Google Scholar
• Dong, L., et al., 2020. A positive feedback loop of lncRNA DSCR8/miR-98-5p/STAT3/HIF-1alpha plays a role in the progression of ovarian cancer. Frontiers in oncology, 10, 1713.
   PubMed Web of Science ®Google Scholar
• Durfee, P.N., et al., 2016. Mesoporous silica nanoparticle-supported lipid bilayers (protocells) for active targeting and delivery to individual leukemia cells. ACS nano, 10 (9), 8325–8345.
   PubMed Web of Science ®Google Scholar
• Foxler, D.E., et al., 2018. A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia. EMBO molecular medicine, 10 (8), e8304.
   PubMedGoogle Scholar
• Fu, M., et al., 2020. Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer. Journal of drug targeting, 28 (3), 245–258.
   PubMed Web of Science ®Google Scholar
• Gluck, S., 2014. nab-Paclitaxel for the treatment of aggressive metastatic breast cancer. Clinical Breast Cancer, 14, 221–227.
   PubMed Web of Science ®Google Scholar
• Grunewald, T., and Ledermann, J.A., 2017. Targeted therapies for ovarian cancer. Best practice & research clinical obstetrics & gynaecology, 41, 139–152.
   PubMed Web of Science ®Google Scholar
• Guardiola, S., et al., 2018. Blocking EGFR activation with anti-EGF nanobodies via two distinct molecular recognition mechanisms. Angewandte chemie (International ed. in English), 57 (42), 13843–13847.
   PubMedGoogle Scholar
• Guo, L., et al., 2019. Tunneling nanotubular expressways for ultrafast and accurate M1 macrophage delivery of anticancer drugs to metastatic ovarian carcinoma. ACS nano, 13 (2), 1078–1096.
   PubMed Web of Science ®Google Scholar
• Harter, P., et al., 2019. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. The new England journal of medicine, 380 (9), 822–832.
   PubMed Web of Science ®Google Scholar
• He, L., et al., 2019. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics, 9 (26), 8206–8220.
   PubMed Web of Science ®Google Scholar
• Jeleniewicz, W., et al., 2019. MMP-2 mRNA expression in ovarian cancer tissues predicts patients' response to platinum-taxane chemotherapy. Anticancer research, 39 (4), 1821–1827.
   PubMed Web of Science ®Google Scholar
• Kesharwani, S.S., et al., 2018. Overcoming multiple drug resistance in cancer using polymeric micelles. Expert opinion on drug delivery, 15 (11), 1127–1142.
   PubMed Web of Science ®Google Scholar
• Kessenbrock, K., Plaks, V., and Werb, Z., 2010. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141 (1), 52–67.
   PubMed Web of Science ®Google Scholar
• Kong, L., et al., 2020. Tumor microenvironmental responsive liposomes simultaneously encapsulating biological and chemotherapeutic drugs for enhancing antitumor efficacy of NSCLC. International journal of nanomedicine, 15, 6451–6468.
   PubMed Web of Science ®Google Scholar
• Lheureux, S., Braunstein, M., and Oza, A.M., 2019a. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: A cancer journal for clinicians, 69 (4), 280–304.
   PubMed Web of Science ®Google Scholar
• Lheureux, S., et al., 2019b. Epithelial ovarian cancer. Lancet (London, England), 393 (10177), 1240–1253.
   PubMed Web of Science ®Google Scholar
• Liu, Q., et al., 2018. Nanocarrier-mediated chemo-immunotherapy arrested cancer progression and induced tumor dormancy in desmoplastic melanoma. ACS nano, 12 (8), 7812–7825.
   PubMed Web of Science ®Google Scholar
• Liu, Q., et al., 2020. Emodin reduces breast cancer lung metastasis by suppressing macrophage-induced breast cancer cell epithelial-mesenchymal transition and cancer stem cell formation. Theranostics, 10 (18), 8365–8381.
   PubMed Web of Science ®Google Scholar
• Liu, S., et al., 2019. S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer. Cell death & disease, 10 (3), 200.
   PubMedGoogle Scholar
• Liu, X., et al., 2017. Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer. Oncotarget, 8 (30), 50209–50220.
   PubMedGoogle Scholar
• Lu, F., et al., 2016. Olig2-dependent reciprocal shift in PDGF and EGF receptor signaling regulates tumor phenotype and mitotic growth in malignant glioma. Cancer cell, 29 (5), 669–683.
   PubMedGoogle Scholar
• Lueckheide, M., et al., 2018. Structure–property relationships of oligonucleotide polyelectrolyte complex micelles. Nano letters, 18 (11), 7111–7117.
   PubMedGoogle Scholar
• Mitchell, R.A., Luwor, R.B., and Burgess, A.W., 2018. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics. Experimental cell research, 371 (1), 1–19.
   PubMed Web of Science ®Google Scholar
• Nilsson, M.B., et al., 2017. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with beta-blockers. Science translational medicine, 9 (415), eaao4307.
   Google Scholar
• Ogiso, H., et al., 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110 (6), 775–787.
   PubMed Web of Science ®Google Scholar
• Park, J., et al., 2019. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics, 9 (26), 8073–8090.
   PubMed Web of Science ®Google Scholar
• Peng, F., et al., 2019. Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness. Nature nanotechnology, 14 (3), 279–286.
   PubMed Web of Science ®Google Scholar
• Rochefort, P., et al., 2017. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. British journal of cancer, 116 (3), 356–361.
   PubMedGoogle Scholar
• Semenza, G.L., 2019. Pharmacologic targeting of hypoxia-inducible factors. Annual review of pharmacology and toxicology, 59, 379–403.
   PubMed Web of Science ®Google Scholar
• Song, Y., et al., 2019. Magnetic liposomal emodin composite with enhanced killing efficiency against breast cancer. Biomaterials science, 7 (3), 867–875.
   PubMed Web of Science ®Google Scholar
• Torre, L.A., et al., 2018. Ovarian cancer statistics, 2018. CA: A cancer journal for clinicians, 68 (4), 284–296.
   PubMed Web of Science ®Google Scholar
• Vos, M.C., et al., 2019. Polymorphisms in MMP-14 and MMP-2 genes and ovarian cancer survival. Cancer biomarkers: section A of disease markers, 25 (3), 233–241.
   PubMedGoogle Scholar
• Vuong, L., et al., 2019. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer discovery, 9 (10), 1349–1357.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2019. Promotion of ovarian cancer cell invasion, migration and colony formation by the miR-21/Wnt/CD44v6 pathway. Oncology reports, 42 (1), 91–102.
   PubMed Web of Science ®Google Scholar
• Yin, M., et al., 2016. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. The journal of clinical investigation, 126 (11), 4157–4173.
   PubMed Web of Science ®Google Scholar
• Yokoi, A., et al., 2017. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer. Nature communications, 8, 14470.
   PubMed Web of Science ®Google Scholar
• Yung, M.M., et al., 2018. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade. Theranostics, 8 (5), 1270–1285.
   PubMed Web of Science ®Google Scholar
• Zaoui, K., et al., 2019. Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion. Nature communications, 10 (1), 2666.
   PubMedGoogle Scholar